Immunology and inflammation

News

Immune checkpoint enhancer biotech AltruBio raises $225m

A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.

News

MS and fibrosis drug developer Contineum files $150m IPO

Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

News

Lawsuit claims J&J illegally delayed Stelara biosimilars

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent

Immune checkpoint enhancer biotech AltruBio raises $225m

MS and fibrosis drug developer Contineum files $150m IPO

AAD: Sanofi showcases data on possible Dupixent successor

AbbVie inks $713m deal for OSE chronic inflammation drug

FDA changes its mind and approves Takeda’s Eohilia

Lawsuit claims J&J illegally delayed Stelara biosimilars

BioNTech sticks with cancer vaccine despite trial miss

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks